Ann: Commencement of sales of cannaQIX 50 in Australia with BHC, page-7

Exciting development imo
About cannaQIX® 50/

LozaCan cannaQIX® 50 is Creso Pharma’s proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain. Each cannaQIX® 50 lozenge contains 50mg of CBD from full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardized pharma-grade formulation produced in Switzerland.

cannaQIX® 50 comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth. This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver.

By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX® 50 lozenges taste great and are a patientfriendly way to administer precise doses of CBD when compared to oil-based alternatives.